Eli Lilly and Company

Freddie Craig Stevens

Cynthia Darshini Jesudason

Daniel Jon Sall

John Arnold Werner

Patrick Gianpietro Spinazze

Don Richard Finley

Jolie Anne Bastian

Vincent Patrick Rocco

Theo Schotten

Richard Todd Pickard

Andrew Michael Ratz

Robert Alan Gadski

Lisa Selsam Beavers

John Xiaoqiang He

William George Trankle

Gerd Reuhter

Paul Leslie Ornstein

Jon Kevin Reel

Philip Arthur Hipskind

Leonard Larry Winneroski, Jr

Matthew Joseph Fisher

Timothy Paul Burkholder

Joseph P Burkhart

Warren Jaye Porter

Yao-Chang Xu

William Joseph Hornback

Yanping Xu

Karin Briner

Shawn Christopher Miller

Thomas John Bleisch

Daniel Ray Mayhugh

Sean Patrick Hollinshead

Serge Louis Boulet

Kevin Matthew Gardinier

Jeffrey Michael Schkeryantz

Jeffrey Thomas Mullaney

Takako Takakuwa

Patric James Hahn

Terry Patrick Finn

Roger Ryan Rothhaar

Douglas Linn Gernert

Albert Khilevich

Matthew Robert Reinhard

Grant Mathews Vaught

William Harlan Gritton

Rushad Eruch Karanjawala

Britta Evers

Brian Eugene Cunningham

Jeffrey Michael Witkin

The present invention provides a compound of Formula (I) wherein R is (II) or (III), or a pharmaceutically acceptable salt thereof, useful for treating psoriasis, systemic lupus erythematosus, or type 1 diabetes.

Substituted 7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives for treating autoimmune diseases

A TARP &#x3b3;8 dependant AMPA receptor antagonist of the formula: wherein X is CH or N;A is andRis as defined herein;its pharmaceutically acceptable salts, uses, and methods for its preparation are described.

[object Object]

The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. 

Pyrrolidine derivatives as histamine H3 receptor antagonists

The present invention provides novel compounds with histamine-H3 receptor antagonist or inverse agonist activity. In particular, the invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the compounds, methods of treatment employing these compounds and compositions, and intermediates and methods for making these compounds. The invention provides methods of using compounds and pharmaceutical compositions to treat obesity, cognitive deficiences, narcolepsy, and other histamine H3 receptor-related diseases. 

Histamine H3 receptor inhibitors, preparation and therapeutic uses

The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. 

Histamine H3 receptor agents, preparation and therapeutic uses

The present invention discloses novel aryl oxazole compounds of Formula I (I), or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing and using such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. Formula I (I) or a pharmaceutically acceptable salt thereof, wherein: m is independenlly at each occurrence 1, 2, or 3, Z independently represents carbon (substituted with hydrogen or the optional substituents indicated herein) or nitrogen, provided that when Z is nitrogen then R6 is not attached to Z; R1 and R2 are independently &#x2014;(C&#x2014;C) alkyl (optionally substituted with one to three halogens), or R1 and R2 and the nitrogen to which they are attached form an azetidinyl ring, a pyrrolidinyl ring, or a piperidinyl ring, wherein further the azetidinyl, pyrrolidinyl, or piperidinyl ring so formed may be optionally substituted one to three times with R5; R6 is independently at each occurrence &#x2014;H, -halogen, or &#x2014;CH. 

Oxazole derivatives as histamine H3 receptor agents, preparation and therapeutic uses

The present invention relates to a &#x3b2;3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful, e.g., for treating Type 2 diabetes and/or obesity 

&#x3b2;3 adrenergic agonists

The present invention relates to a &#x3b2;adrenergic receptor agonist of formula I: or a pharmaceutical salt thereof; which is useful for treating Type II diabetes and/or obesity.

The present invention relates to a &#x3b2;3 adrenergic receptor agonist of formula I: or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.

3-substituted oxindole &#x3b2;3 agonists

The present invention relates to a &#x3b2;3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.

3-substituted oxindole &#x3b2;-3 agonists

The present invention provides serotonergic benzofurans of Formula (I): where A, R, R, R, R, and Rare as described in the specification.

Serotonergic benzofurans

The present invention relates to a &bgr;;3 adrenergic receptor agonist of formula I: (1); or a pharmaceutical salt thereof; which is useful for treating Type II diabetes and/or obesity.

3-Substituted oxindole &bgr; 3 agonists

Growing community of inventors

Indianapolis, IN, United States of America

Freddie Craig Stevens